Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy.
J Exp Med. 2017.
PMID: 28028152
Free PMC article.
Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2024 | 0 |
Search Results
2 results
Results by year
Citations
1
article
found by citation matching
Search results
Filters applied: . Clear all
Page 1
Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy.
Sha L, Wang X, Li J, Shi X, Wu L, Shen Y, Xu Q.
Sha L, et al.
J Exp Med. 2017 Feb;214(2):547-563. doi: 10.1084/jem.20160667. Epub 2016 Dec 27.
J Exp Med. 2017.
PMID: 28028152
Free PMC article.
Mechanistically, Hsp90beta recruits GLT-1 to the 20S proteasome, thereby promoting GLT-1 degradation. Hsp90 inhibitor prevents GLT-1 degradation by disrupting the association between Hsp90beta and GLT- …
Mechanistically, Hsp90beta recruits GLT-1 to the 20S proteasome, thereby promoting GLT-1 degradation. …
Item in Clipboard
Hsp90beta inhibitors prevent GLT-1 degradation but have no beneficial efficacy on absence epilepsy.
Peng YC, Wang S, Zhang Y, Huang LJ, Wang XL, Peng Y.
Peng YC, et al.
J Asian Nat Prod Res. 2019 Sep;21(9):905-915. doi: 10.1080/10286020.2018.1530989. Epub 2018 Nov 17.
J Asian Nat Prod Res. 2019.
PMID: 30450970
The loss of glutamate transporter-1 (GLT-1) is associated with temporal lobe epilepsy (TLE). A recent study reported that Hsp90beta interacted with GLT-1 and recruited it to 20S proteasome for degradation. Therefore, inhibiting Hsp …
The loss of glutamate transporter-1 (GLT-1) is associated with temporal lobe epilepsy (TLE). A recent study reported th …
Item in Clipboard
Cite
Cite